A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.

被引：15
|
作者：
Gabrail, Nashat Y.
Hamilton, Erika P.
Elias, Anthony D.
Rimawi, Mothaffar F.
Li, Chao
Corvez, Maria Margarita
Li, Wei
Feng, Ying
Wei, Jiao
Greene, Stephanie
Patterson, John
Zeng, Qingping
Hui, Ai-Min
机构：
[1] Gabrail Canc Ctr Res LLC, Canton, OH USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Tennessee Oncol PLLC, Nashville, TN USA
[4] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA
[5] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA
[6] Shanghai Fosun Pharmaceut Dev Co Ltd, Shanghai, Peoples R China
[7] Orinove Inc, Newbury, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3080
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Jonasch, Eric
    Zojwalla, Naseem J.
    Wang, Keshi
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] A phase 1 study of oral navelbine in patients with advanced solid tumors.
    Rajdev, L
    Dai, Q
    Mani, S
    Goldberg, G
    Baker, C
    Hoschander, S
    Sparano, J
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6137S - 6137S
  • [43] Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.
    Wang, Judy Sing-Zan
    Barve, Minal A.
    Chiorean, E. Gabriela
    LoRusso, Patricia
    Courtney, Kevin Dale
    Qi, Dan
    Olguin, Arturo
    Bullington, John
    Sardone, Megan
    Dunn, Vanessa
    Shemesh, Shay
    Chen, Janice
    Brooks, Christopher
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.
    Johnson, Melissa Lynne
    Patel, Manish R.
    Siu, Lillian L.
    Kozloff, Mark
    Aljumaily, Raid
    Vaishampayan, Ulka N.
    Elgadi, Mabrouk M.
    Ge, Miaomiao
    Duffy, Christine
    Graeser, Ralph
    Khedkar, Sheetal Vinay
    Jones, Suzanne Fields
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [45] A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors
    Laurie, Scott Andrew
    Jonker, Derek J.
    Edenfield, William Jeffery
    Stephenson, Joe
    Keller, Deborah
    Hitron, Matthew
    Li, Wei
    Li, Youzhi
    Gada, Keyur
    Gao, Yuan
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.
    Dolly, S. O.
    Albanell, J.
    Kraeber-Bodere, F.
    Banerji, U.
    Bahleda, R.
    Garcia, M. Martinez
    Xu, Z. X.
    Guarin, E.
    Tessier, J.
    Shochat, E.
    Deutsch, J.
    Blotner, S.
    Meresse, V.
    Soria, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
    Berdeja, Jesus G.
    Dingli, David
    Lonial, Sagar
    Yee, Andrew J.
    Chung, Alfred
    Gasparetto, Cristina
    Leif Bergsagel, P.
    Roy, Vivek
    Abdallah, Al-Ola
    Thanendrarajan, Sharmilan
    Afrough, Aimaz
    Rosinol, Laura
    Trudel, Suzanne
    Rodriguez Otero, Paula
    Touzeau, Cyrille
    Bories, Pierre
    Bang, Soo
    Connolly, Terry
    Kim, Michelle
    Lewis, Chad A.
    Linberg, Bao-Van Tran
    Travis Quigley, M.
    Landgren, Ola
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    Siegel, David S.
    BLOOD, 2023, 142
  • [48] Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
    Eskens, Ferry A. L. M.
    Ramos, Francisco J.
    Burger, Herman
    O'Brien, James P.
    Piera, Adelaida
    de Jonge, Maja J. A.
    Mizui, Yoshiharu
    Wiemer, Erik A. C.
    Carreras, Maria Josepa
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6296 - 6304
  • [49] FIRST-IN-HUMAN PHASE 1/2 STUDY OF THE FIRST-IN-CLASS SUMO-ACTIVATING ENZYME INHIBITOR TAK-981 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS OR RELAPSED/REFRACTORY LYMPHOMA: PHASE 1 RESULTS
    Dudek, Arkadiusz
    Juric, Dejan
    Dowlati, Afshin
    Vaishampayan, Ulka
    Assad, Hadeel
    Rodon, Jordi
    Chao, Bo
    Wang, Bingxia
    Gibbs, John
    Shinde, Vaishali
    Friedlander, Sharon
    Berger, Allison
    Ward, Christine
    Martinez, Alonzo
    Gharavi, Robert
    Gomez-Pinillos, Alejandro
    Proscurshim, Igor
    Olszanski, Anthony
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A505 - A506
  • [50] Phase 1 study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors.
    Rha, Sun Young
    Beom, Seung-Hoon
    Jung, Minkyu
    Shin, Young Geun
    Cheong, Jae-Ho
    Kim, Hyo Song
    Kim, Gun Min
    Chang, Jong Hee
    Lee, Young Woo
    Chong, Yunseon
    Yoo, Sanghee
    O'Neil, Vincent
    Janku, Filip
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345